MedTrace Logo

Toviaz Post Marketing Surveillance Study

NCT00879398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2015-10-21

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine the problems and questions of safety and efficacy of Toviaz® under the standard conditions of usage.

Conditions

Interventions

DRUG

Toviaz treatment

4 mg starting then can be followed by 8 mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00879398 on ClinicalTrials.gov